CMS Implements Moratorium on New DMEPOS Suppliers to Combat Fraud
On February 26, 2026, the Centers for Medicare & Medicaid Services (CMS) announced a temporary halt on the enrollment of new suppliers in the Medicare program's Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) category. This nationwide six-month moratorium arises from CMS's analysis of enrollment and claims data highlighting ongoing program integrity challenges within the DMEPOS supplier sector. Effective from February 27, 2026, the halt aims to mitigate fraud, waste, and abuse risks under the Affordable Care Act's authority, empowering CMS to block enrollments where significant fraud potential is detected.
The CMS, partnering with the Health and Human Services (HHS) Office of Inspector General, identified issues of improper billing and fraudulent practices impacting Medicare funds. HHS Secretary Kennedy and CMS Administrator Oz emphasized the shift towards proactive fraud prevention, utilizing advanced analytics and artificial intelligence to detect suspicious billing at the enrollment stage, thereby averting improper payouts.
This moratorium pertains to all DMEPOS suppliers not yet enrolled as of the notice's publication date but does not affect current suppliers, who may continue Medicare billing. The freeze does not hinder practice location changes, ownership transfers, or administrative updates that don't require new enrollment. Applications submitted before the moratorium's effective date continue through the approval process, subject to specific exceptions.
CMS maintains the authority to extend the temporary moratorium in six-month increments, with further announcements made via the Federal Register. Businesses aiming to enter the Medicare DMEPOS market should anticipate delays and uncertainties in application timelines and assess their operations accordingly.
Existing suppliers should prepare for increased monitoring of their billing and compliance procedures, underscoring the importance of maintaining robust oversight mechanisms. While the current moratorium targets DMEPOS providers, CMS's statutory authority could enable similar moratoria in other sectors if future data indicates risks.
The DMEPOS enrollment freeze signifies a strengthened commitment by federal agencies to enhance Medicare integrity oversight and secure beneficiary protections. Suppliers and industry stakeholders must stay vigilant and responsive to evolving regulatory developments.
The moratorium coincides with the CMS Request for Information (RFI) under the Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH) initiative. This effort seeks feedback from industry stakeholders to inform potential regulatory enhancements aimed at comprehensive fraud prevention across several healthcare programs, including Medicare, Medicaid, and the Health Insurance Marketplace. The CRUSH initiative represents a strategic alignment of immediate enforcement measures with long-term regulatory evolution to solidify anti-fraud frameworks.